On June 4, 2024, the National Advertising Division (“NAD”), a self-regulatory forum for competitive advertising disputes, recommended that a breast cancer genomic test manufacturer (“Advertiser”) modify or discontinue several claims regarding the superiority of its tests for Black women, including claims that a competitor’s (“Challenger”) test is “inappropriate for women and that it is... READ MORE
NAD Recommends that Medical Device Manufacturer Discontinue Advertising Claims Following Competitor Challenge
Posted on July 11, 2024 in Health Law News
Published by: Hall Render
